on Viromed Medical AG (isin : DE000A3MQR65)
Viromed Medical AG Revises Revenue Forecast for 2026 Amid Growth
Viromed Medical AG, a leader in cold plasma medical technology, reported a significant revenue increase for the 2025 financial year, although it missed initial projections. Revenue soared from €1.1 million in 2024 to €5.1 million in 2025, while net income hit €0.6 million, surpassing forecasts despite revenues falling short of the targeted €8-10 million range.
Challenges in launching ViroCAP® and gaining approval for PulmoPlas® led to a revised 2026 forecast, previously set at €80 million with a double-digit EBIT margin. However, the company remains optimistic about leveraging its high market potential driven by distribution partnerships and interest in cold plasma technology applications.
Viromed anticipates substantial increases in revenue and net income for 2026, with audited results for 2025 expected by May 22, 2026.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Viromed Medical AG news